Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: January 15, 2008
Last updated: April 21, 2017
Last verified: April 2017
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies.

Condition Intervention Phase
Breast Cancer
Breast Neoplasms
Colon Cancer
Colonic Cancer
Colon Neoplasms
Lung Cancer
Kidney Cancer
Drug: AZD6244
Drug: Dacarbazine
Drug: Erlotinib
Drug: Docetaxel
Drug: Temsirolimus
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies. [ Time Frame: 28 days + ]
    Incidence and intensity of adverse events as graded by CTCAE (version 3.0), physical examinations, vital signs (including weight, blood pressure and pulse rate), ECG parameters, MUGA scan and echocardiography, clinical chemistry (including liver function tests), Brain Natriuretic Peptide (BNP), Troponin I, hematology, urinalysis, and ophthalmologic examinations.

Secondary Outcome Measures:
  • PK of AZD6244 and selected chemotherapies. [ Time Frame: Cycle 1 Day 3 and Cycle 2 day 1 ]
    The PK parameters will be derived using noncompartmental analysis. The maximum plasma concentrations (Cmax) and the time to reach the maximum plasma concentrations (tmax) will be determined by visual inspection of the plasma concentration-time profiles. The area under the plasma concentration-time curve from zero to 12 hours post dose, AUC(0-12), will be calculated by the linear trapezoidal rule. Where more than one maxima occurs, the reported value will be assigned to the first occurrence.

  • Define highest tolerated dose of AZD6244 when in combination with selected chemotherapies. [ Time Frame: 28 days + ]
    The starting dose of AZD6244 in each arm will be 50mg. Continuous dosing (commencing Cycle 1/Day 3 for docetaxel and dacarbazine and Cycle 1/Day 8 for erlotinib and temsirolimus) will be BD. The AZD6244 dose may be maintained or reduced.

  • Tumor response. [ Time Frame: 28 days + ]
    To make a preliminary assessment of tumor response as measured by Objective Response Rate (ORR) per investigator's assessment using Response Evaluation Criteria in Solid Tumors (RECIST) when AZD6244 Hyd-Sulfate is given in combination with standard doses of selected chemotherapies.

Enrollment: 211
Actual Study Start Date: December 14, 2007
Estimated Study Completion Date: December 29, 2017
Primary Completion Date: August 20, 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AZD6244 + docetaxel
Drug: AZD6244
twice daily oral dose
Other Name: ARRY-142886
Drug: Docetaxel
intravenous infusion
Other Name: Taxotere®
Experimental: 2
AZD6244 + Dacarbazine
Drug: AZD6244
twice daily oral dose
Other Name: ARRY-142886
Drug: Dacarbazine
intravenous infusion
Experimental: 3
AZD6244 + Erlotinib
Drug: AZD6244
twice daily oral dose
Other Name: ARRY-142886
Drug: Erlotinib
daily oral dose
Experimental: 4
AZD6244 + Temsirolimus
Drug: AZD6244
twice daily oral dose
Other Name: ARRY-142886
Drug: Temsirolimus
intravenous infusion


Ages Eligible for Study:   18 Years to 130 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care
  • WHO performance status 0-1
  • Patients must be able to swallow AZD6244 capsules

Exclusion Criteria:

  • Prior treatment with a MEK inhibitor
  • Participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug
  • Brain metastases or spinal cord compression unless treated and stable (for at least 1 month) off steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00600496

United States, Michigan
Research Site
Detroit, Michigan, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Houston, Texas, United States
Sponsors and Collaborators
Principal Investigator: Patricia LoRusso, DO Barbara Ann Karmanos Cancer Institute
Principal Investigator: Roger Cohen, MD Fox Chase Cancer Center
Principal Investigator: Jeffrey Infante, MD SCRI Development Innovations, LLC
Principal Investigator: Kevin Kim, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT00600496     History of Changes
Other Study ID Numbers: D1532C00004
Study First Received: January 15, 2008
Last Updated: April 21, 2017

Keywords provided by AstraZeneca:
Colon Cancer
Breast Cancer
Lung Cancer
Kidney Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Breast Neoplasms
Kidney Neoplasms
Carcinoma, Renal Cell
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Breast Diseases
Skin Diseases
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial processed this record on April 24, 2017